Phase 1 trial of DS-9606 states promising preliminary clinical activity in advanced solid tumours patients

Initial results from the phase 1 trial of DS-9606 indicate promising clinical activity in patients with advanced solid tumors expressing Claudin-6 (CLDN6). Presented at the 2024 European Society for Medical Oncology, the study demonstrated that a single dose of DS-9606 significantly reduced the likelihood of influenza transmission among household members.

DS-9606, a CLDN6-directed antibody-drug conjugate (ADC) from Daiichi Sankyo, is being evaluated for safety, tolerability, and efficacy in adult patients. The trial enrolled 53 heavily pretreated participants, revealing no dose-limiting toxicities and common treatment-related adverse events like nausea and fatigue.

Preliminary efficacy results showed confirmed responses in four patients at doses of 0.072 mg/kg or higher, with two patients with germ cell tumors remaining on treatment for over six months. The trial is currently recruiting patients in Europe and North America and aims to establish the maximum tolerated dose for further evaluation.

Daiichi Sankyo is committed to advancing healthcare by developing innovative therapies that enhance quality of life.